Bio-Rad Laboratories, Inc. (BIO.B) stock
BIO.BNYSELaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BIO
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 8/3055% above fair value
$379.50+0.00 (0.00%)
Close on Oct 29, 2026Market cap $10.18BP/E 46.2Yield –
Bio-Rad Laboratories free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Bio-Rad Laboratories's free cash flow for the twelve months ending Jun 30, 2026 was $353.10M, down 4.8% year over year. For fiscal 2025 it was $374.60M, up 29.4% from the year before. Over ten years it grew 17.6% a year on average. The highest annual figure on record is $535.72M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $374.60M | +29.4% |
| FY2024 | Dec 31, 2024 | $289.60M | +32.7% |
| FY2023 | Dec 31, 2023 | $218.20M | +167.4% |
| FY2022 | Dec 31, 2022 | $81.60M | -84.8% |
| FY2021 | Dec 31, 2021 | $535.72M | +12.4% |
| FY2020 | Dec 31, 2020 | $476.41M | +32.6% |
| FY2019 | Dec 31, 2019 | $359.37M | +130.9% |
| FY2018 | Dec 31, 2018 | $155.67M | – |
| FY2017 | Dec 31, 2017 | -$7.20M | -109.6% |
| FY2016 | Dec 31, 2016 | $74.63M | +0.6% |
| FY2015 | Dec 31, 2015 | $74.21M | -51.3% |
| FY2014 | Dec 31, 2014 | $152.31M | +143.8% |
| FY2013 | Dec 31, 2013 | $62.48M | -49.5% |
| FY2012 | Dec 31, 2012 | $123.61M | -22.7% |
| FY2011 | Dec 31, 2011 | $159.85M | +16.3% |
| FY2010 | Dec 31, 2010 | $137.46M | -46.5% |
| FY2009 | Dec 31, 2009 | $257.03M | -6.9% |
| FY2008 | Dec 31, 2008 | $276.18M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $66.70M | -5.8% |
| Q1 FY2026 | Mar 31, 2026 | $78.10M | -18.2% |
| Q4 FY2025 | Dec 31, 2025 | $119.10M | +46.5% |
| Q3 FY2025 | Sep 30, 2025 | $89.20M | -27.7% |
| Q2 FY2025 | Jun 30, 2025 | $70.80M | +28.0% |
| Q1 FY2025 | Mar 31, 2025 | $95.50M | +222.6% |
| Q4 FY2024 | Dec 31, 2024 | $81.30M | +109.9% |
| Q3 FY2024 | Sep 30, 2024 | $123.40M | +130.1% |
| Q2 FY2024 | Jun 30, 2024 | $55.30M | -12.8% |
| Q1 FY2024 | Mar 31, 2024 | $29.60M | -52.6% |
| Q4 FY2023 | Dec 31, 2023 | $38.74M | -13.5% |
| Q3 FY2023 | Sep 30, 2023 | $53.64M | – |
| Q2 FY2023 | Jun 30, 2023 | $63.43M | +76.5% |
| Q1 FY2023 | Mar 31, 2023 | $62.39M | +258.3% |
| Q4 FY2022 | Dec 31, 2022 | $44.80M | -60.9% |
| Q3 FY2022 | Sep 30, 2022 | -$16.55M | -108.5% |
| Q2 FY2022 | Jun 30, 2022 | $35.94M | -72.6% |
| Q1 FY2022 | Mar 31, 2022 | $17.42M | -81.5% |
| Q4 FY2021 | Dec 31, 2021 | $114.68M | -53.3% |
| Q3 FY2021 | Sep 30, 2021 | $195.74M | +69.2% |
| Q2 FY2021 | Jun 30, 2021 | $131.24M | +77.3% |
| Q1 FY2021 | Mar 31, 2021 | $94.06M | +128.2% |
| Q4 FY2020 | Dec 31, 2020 | $245.50M | +77.6% |
| Q3 FY2020 | Sep 30, 2020 | $115.69M | +68.5% |
| Q2 FY2020 | Jun 30, 2020 | $74.01M | -44.4% |
| Q1 FY2020 | Mar 31, 2020 | $41.22M | +113.4% |
| Q4 FY2019 | Dec 31, 2019 | $138.20M | +170.3% |
| Q3 FY2019 | Sep 30, 2019 | $68.66M | +70.7% |
| Q2 FY2019 | Jun 30, 2019 | $133.19M | +160.4% |
| Q1 FY2019 | Mar 31, 2019 | $19.31M | +46.7% |
| Q4 FY2018 | Dec 31, 2018 | $51.14M | +18.1% |
| Q3 FY2018 | Sep 30, 2018 | $40.22M | +392.8% |
| Q2 FY2018 | Jun 30, 2018 | $51.15M | +38.7% |
| Q1 FY2018 | Mar 31, 2018 | $13.16M | – |
| Q4 FY2017 | Dec 31, 2017 | $43.30M | -12.8% |
| Q3 FY2017 | Sep 30, 2017 | $8.16M | -32.8% |
| Q2 FY2017 | Jun 30, 2017 | $36.88M | – |
| Q1 FY2017 | Mar 31, 2017 | -$95.54M | – |
| Q4 FY2016 | Dec 31, 2016 | $49.64M | – |
| Q3 FY2016 | Sep 30, 2016 | $12.15M | – |